A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Ipilimumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 10 Jun 2017 Biomarkers information updated
- 18 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Jul 2019.
- 10 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.